###### Article Summary

Article focus
=============

-   Does peri-operative anabolic steroid administration improve patient outcomes following total knee arthroplasty?

-   Are peri-operative anabolic steroids associated with increased adverse effects?

Key messages
============

-   There is insufficient trial data to recommend peri-operative anabolic steroids in patients undergoing total knee arthroplasty.

-   Pilot studies suggest anabolic steroids can enhance recovery in these patients.

-   A trial of greater power is necessary to confirm these findings and identify rare adverse events.

Strengths and limitations of this study
=======================================

-   The number of patients studied so far is very small and insufficient to guide practice.

-   Trial heterogeneity prevented a meaningful meta-analysis.

Background {#s1}
==========

Total knee replacement (TKR) is a common treatment for end-stage knee osteoarthritis (OA). Joint replacement registries report increasing numbers of TKR operations, which are projected to rise by 673% to 3.48 million procedures in the USA alone by 2030.[@R1] Although TKR is safe and effective,[@R2] [@R3] a significant number of patients experience continued functional limitation after surgery.[@R4; @R5; @R6]

Quadriceps weakness is common after TKR, even following extensive rehabilitation.[@R7] [@R8] Lower limb weakness is correlated with diminished functional performance, gait asymmetries and postural instability.[@R9] A number of strategies have been used to mitigate lower limb muscle weakness, including lower-limb strengthening[@R10] and neuromuscular electrical stimulation.[@R11] [@R12] However, these techniques have only achieved modest improvements in rehabilitation post-TKR.[@R10; @R11; @R12]

Androgenic-anabolic steroids (AAS) are a potential means of reducing quadriceps weakness post-TKR.[@R13] [@R14] They have been used successfully to treat other patient groups suffering from muscle atrophy, such as those with HIV/AIDS,[@R15] renal failure,[@R16] chronic obstructive pulmonary disease[@R17] and muscle contusion injuries.[@R18] AAS are a group of chemically related structures derived from the male sex hormone, testosterone. They are defined by their ability to promote muscle growth (anabolic properties) and masculinisation (androgenic properties). Evidence from athlete populations suggests AAS use can achieve significant increases in lean body mass and strength gains of up to 20%.[@R19] Although reportedly associated with a number of adverse effects, these anabolic properties raise the possibility of improving postoperative muscle weakness following TKR.

This review sought to evaluate the available evidence for using AAS in patients undergoing TKR.

Methods {#s2}
=======

We devised a systematic review protocol according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@R20] The search strategy and eligibility criteria were determined in advance of implementation.

Eligibility criteria {#s2a}
--------------------

All prospective and retrospective studies reporting the effects of AAS on physiological and functional outcomes after total knee arthroplasty were included. No language or patient demographic (eg, age and sex) limits were applied, although results were limited to studies of human participants. The predetermined outcomes were: All functional outcomes, for example, walking speed, stairs, activities of daily living.Relevant physiological outcomes, for example, muscle strength.Length of hospital stay and need for inpatient rehabilitation.Adverse effects.

Study identification {#s2b}
--------------------

MEDLINE (1950--), EMBASE (1974--), AMED (1985--), CINAHL (1981--) and the Cochrane Library (1993--) were searched from inception to August 2012. Reference lists were used to identify any additional studies. The search strategy was: knee replacement ORknee arthroplasty ANDtestosterone ORanabolic steroids ORanabolic--androgenic steroids

Study selection {#s2c}
---------------

Two reviewers independently screened titles and abstracts to identify studies meeting the inclusion criteria.

Data extraction {#s2d}
---------------

Two authors (DM and EW) independently extracted data from selected studies and there were no disagreements.

Results {#s3}
=======

Five database entries were retrieved using the search strategy, of which only three were unique on elimination of duplicates. Only two ([table 1](#BMJOPEN2012001435TB1){ref-type="table"}) satisfied the inclusion criteria ([figure 1](#BMJOPEN2012001435F1){ref-type="fig"}), the third being a laboratory study. Both studies were small randomised controlled trials comparing peri-operative intramuscular testosterone against placebo in patients undergoing TKR.

###### 

Studies meeting the review inclusion criteria

  Study                   Study type                         Participants                                       Intervention                                                                           Outcome measures
  ----------------------- ---------------------------------- -------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Hohmann *et al*[@R14]   Randomised, double-blinded trial   10 Participants. Mean age 65.7 (range 58--72)      50 mg nandrolone decanoate intramuscularly bi-weekly for 6 months                      Knee society score; isokinetic strength testing; functional tests (sit-to-stand, timed walk); bone mineral density
  Amory *et al*[@R13]     Randomised, double-blinded trial   25 Male participants. Mean age 70 (range 58--86)   600 mg testosterone enanthate intramuscularly once weekly for 4 weeks preoperatively   Length of hospital stay; functional tests

![Flow diagram showing inclusion and exclusion of items retrieved from a systematic literature search.](BMJOPEN2012001435f01){#BMJOPEN2012001435F1}

As there was significant heterogeneity between the studies in terms of reported outcomes, data were not pooled and no statistical interpretation was attempted.

Physiological outcomes {#s3a}
----------------------

### Thigh strength {#s3a1}

Hohmann *et al*[@R14] assessed quadriceps and hamstring strength using peak torque measured with a Biodex Isokinetic Dynamometer. The groups improved steadily across both measures but recovery was accelerated in the AAS group. They found statistically significant differences in quadriceps strength between the groups at 3 (p=0.02), 6 (p=0.01) and 12 (p=0.02) months, although differences in hamstring strength were not statistically significant. The AAS group surpassed preoperative quadriceps strength by 3 months and hamstring torque by 6 months. In contrast, the control participants surpassed preoperative quadriceps strength by 6 months but did not regain preoperative hamstring strength within the 12-month study period.

### Bone mineral density {#s3a2}

Only Hohmann *et al*[@R14] attempted to determine AAS impact on bone mineral density. Patients underwent DEXA scanning at the lumbar spine and neck of femur on the affected side 1 week preoperatively and 6 weeks postoperatively. No significant difference was demonstrated between patients receiving AAS and control groups (percentage bone loss femur: AAS 0.71%, control −3.80%; spine: AAS −1.25%, control −1.97%).

### Biochemistry {#s3a3}

Amory *et al*[@R13] measured serum total testosterone, renal function, lipoproteins, haematocrit, glutamic oxaloacetic transaminase and prostate-specific antigen at baseline and five weeks postoperatively. The AAS group showed a significant increase in serum total testosterone preoperatively from 12.5±4.5 to 82.5±16.2 nmol/l. Serum testosterone was not significantly different between the groups or when compared with baseline by 5 weeks postoperatively.

Haematocrit was significantly higher in the AAS group preoperatively (p=\<0.05) but not postoperatively. There were no statistically significant differences observed in high-density lipoprotein, low-density lipoprotein or total cholesterol.

Functional outcomes {#s3b}
-------------------

### Sit-to-stand {#s3b1}

Hohmann *et al*[@R14] conducted a 'sit-to-stand' test modified from Bohannon[@R21] preoperatively and at each follow-up appointment. Patients were invited to stand from a firm, armless chair with their arms crossed, then sit again. The AAS group showed improvement immediately postoperatively at the first (6 weeks) follow-up. In contrast, the control group did not regain preoperative speeds until 9 months. These findings were not statistically significant within the follow-up period (p=0.05).

### Timed walk {#s3b2}

The authors also assessed walking speed across a 10 m marked path and back. Averages of three trials at maximal speed were reported after an initial warm-up lap. They recorded little variation in walking speeds between the two groups and no statistically significant differences.

Outcome scores {#s3c}
--------------

### Functional independence measure {#s3c1}

Amory *et al*[@R13] used the Functional Independence Measure (FIM)---a seven-point scale assessing ability to walk, stand and climb stairs---which was conducted by an investigator blinded to treatment. Both groups had similar preoperative FIM scores which fell postoperatively and neither returned to baseline by 35 days follow-up. However, by day three, participants in the AAS limb were significantly better at standing than the placebo group (FIM 5.2 vs 4.1, p=\<0.05).

### Knee society score {#s3c2}

Hohmann *et al*[@R14] used the Knee Society Score (KSS) and KSS function score. The former uses reported pain, flexion contracture, extension lag, flexion range, stability (anteroposterior and mediolateral) and alignment. There were significant differences in favour of the AAS group at 6 weeks (p=0.02), 6 months (p=0.04) and 12 months (p=0.03). The KSS function score considers ability to walk, climb stairs and use of ambulatory aids. Although the authors reported trends towards greater improvement in the AAS, there were no statistically significant between group differences.

Length of hospital stay {#s3d}
-----------------------

Amory *et al* found that the AAS group had a shorter length of hospital stay (5.9±2.4 days) relative to the control group (6.7±2.5 days). Similarly, a smaller proportion of patients required inpatient rehabilitation (20% vs 25%). However, these findings were not statistically significant.

Adverse effects {#s3e}
---------------

Neither study reported adverse events, side effects or mortality attributable to testosterone administration. In one study,[@R13] an 81-year-old man from the AAS group died from known coronary artery disease 12 months postoperatively. Amory *et al*[@R13] monitored renal and liver function as well as serum prostate-specific antigen and observed no differences.

Discussion {#s4}
==========

We identified a weak evidence base for use of AAS to improve functional and physiological outcomes post-TKR. However, both studies[@R13] [@R14] reported trends towards improvement in their AAS cohorts across all measured outcomes, with the sole exception of timed walking speed. Across the two studies, AAS patients showed greater improvements in postoperative quadriceps and hamstring strength, bone mineral density and sit-to-stand testing. They also scored more highly on the FIM, KSS and KSS function score. AAS patients had a shorter length of hospital stay and less need for inpatient rehabilitation. A number of these observed differences were statistically significant, including quadriceps strength at all time points, standing as assessed by the FIM and KSS score. Between group differences on the sit-to-stand test at 9 months were almost statistically significant (p=0.05). It is possible that other positive effects did not reach significance due to very small sample sizes. Interestingly, neither study reported that the placebo group surpassed the AAS cohort at any point on any of the outcomes tested.

Knee OA is accompanied by marked lower limb weakness which typically worsens after TKR.[@R22] Isometric flexion strength decreases by 17% in operated knees while no significant difference is measured on the contralateral side.[@R23] These deficits persist long into the postoperative period. Operated knees attain hamstring peak torques comparable to the contralateral side after 12 months whereas quadriceps function is still limited two years later.[@R24] Significant improvements have been reported with minimally invasive TKR techniques. For example, patients undergoing TKR using the mini-subvastus technique were found to match preoperative quadriceps strength after only 3 months. Quadriceps strength even surpassed preoperative levels by 17% at 6 and 30% at 12 months.[@R25]

Lower limb muscle strength is important as weakness is accompanied by worse functional outcomes. Both quadriceps and hip abductor strength are independently associated with improved ability to ascend and descend stairs.[@R26] Quadriceps strength is also significantly correlated with walking speed.[@R27] Both preoperative and postoperative quadriceps strength predicts improved functional performance one year after TKR.[@R7] [@R8]

Attempts to improve lower limb muscle strength have achieved mixed success. Randomised trials comparing exercise training pre-TKR with usual care have reported improved lower limb strength, reduced pain and greater function postoperatively in the treated groups.[@R28] [@R29] In contrast, a Cochrane review of two prospective studies on postoperative neuromuscular stimulation reported no significant differences in quadriceps strength.[@R12] A range of laboratory, animal and population studies on athletes have confirmed the ability of AAS to improve muscle strength.[@R19] [@R30] The studies reported in this review support the potential for AAS to improve quadriceps strength and functional outcomes post-TKR.[@R13] [@R14]

AAS can be administered through oral, buccal, intramuscular, subcutaneous or transdermal routes. However, they have been associated with a range of adverse effects. As many as 96% of regular AAS users report one or more objective side effects, commonly including acne, testicular atrophy, injection site pain, cutaneous striae and gynaecomastia.[@R31] Serious adverse effects include hepatic,[@R32] [@R33] cardiovascular[@R19] [@R34] and neuropsychiatric disease.[@R35] [@R36] Long-term use may stimulate myocardial hypertrophy with subsequent myocardial infarction, systolic dysfunction, arrhythmias and sudden death.[@R37] [@R38] There is also a risk of dependence with 84% of athletes reporting withdrawal effects on AAS cessation and 57% satisfying DSM-III criteria for dependence.[@R39]

However, the safety profile is likely to differ between AAS *use* on physician advice and *abuse*. For example, bodybuilders use up to 6000 mg/week testosterone, significantly higher than that administered by Amory *et al* (600 mg) or Hohmann *et al* (50 mg bi-weekly). Over half of bodybuilding users report sourcing AAS from underground laboratory facilities and 96% use other drugs concurrently, such as stimulants, fat loss agents and adjuvant anabolic compounds.[@R40] For these reasons, it is important not to overstate the dangers of AAS use.[@R41] [@R42] Adverse effects are dose-related and largely reversible following cessation of use.[@R43] [@R44] This supports the finding by Amory *et al*[@R13] that serum testosterone did not differ significantly between treated and placebo limbs at five weeks post-TKR. Importantly, researchers using AAS therapeutically in patient populations have not reported adverse effects.[@R13] [@R14; @R15; @R16; @R17; @R18]

The trials selected for this review suggest AAS could help mitigate quadriceps weakness post-TKR and improve functional outcomes. Early mobilisation and rehabilitation are known to shorten hospital length of stay, reduce cost and improve functional performance.[@R45] In the absence of adverse effects reported in patient populations, AAS may provide another tool with which to expedite recovery after TKR. Although there is currently insufficient evidence to recommend the routine use of AAS, this preliminary evidence clearly justifies a randomised trial sufficiently powered to identify between-group differences likely to be of clinical significance.
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